| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Plaque, Atherosclerotic | 137 | 2024 | 1517 | 35.220 |
Why?
|
| Tomography, Optical Coherence | 196 | 2024 | 2873 | 26.180 |
Why?
|
| Coronary Vessels | 147 | 2024 | 3110 | 21.950 |
Why?
|
| Coronary Artery Disease | 148 | 2024 | 6643 | 17.650 |
Why?
|
| Acute Coronary Syndrome | 77 | 2024 | 2363 | 16.030 |
Why?
|
| Coronary Angiography | 144 | 2024 | 4559 | 9.670 |
Why?
|
| Ultrasonography, Interventional | 53 | 2023 | 1502 | 7.110 |
Why?
|
| Coronary Thrombosis | 28 | 2021 | 486 | 6.650 |
Why?
|
| Drug-Eluting Stents | 27 | 2023 | 758 | 6.320 |
Why?
|
| Angioplasty, Balloon, Coronary | 43 | 2018 | 1880 | 5.610 |
Why?
|
| Stents | 58 | 2024 | 3308 | 4.940 |
Why?
|
| Pipecolic Acids | 24 | 2010 | 78 | 4.630 |
Why?
|
| Coronary Stenosis | 23 | 2021 | 818 | 4.350 |
Why?
|
| Myocardial Infarction | 70 | 2024 | 11891 | 3.950 |
Why?
|
| Predictive Value of Tests | 80 | 2024 | 15262 | 3.480 |
Why?
|
| Coronary Restenosis | 19 | 2015 | 425 | 3.250 |
Why?
|
| Heparin | 35 | 2015 | 1656 | 3.180 |
Why?
|
| Neointima | 16 | 2017 | 133 | 3.170 |
Why?
|
| Rupture, Spontaneous | 23 | 2024 | 356 | 2.840 |
Why?
|
| Fibrinolytic Agents | 26 | 2018 | 2168 | 2.680 |
Why?
|
| Cardiac Imaging Techniques | 6 | 2021 | 269 | 2.230 |
Why?
|
| Sirolimus | 19 | 2017 | 1537 | 2.210 |
Why?
|
| Thrombocytopenia | 20 | 2011 | 1174 | 2.190 |
Why?
|
| Lipids | 21 | 2024 | 3337 | 2.120 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 12 | 2020 | 3329 | 2.040 |
Why?
|
| Anticoagulants | 28 | 2015 | 4896 | 2.020 |
Why?
|
| Coronary Circulation | 13 | 2021 | 1576 | 2.020 |
Why?
|
| Thrombosis | 30 | 2023 | 3042 | 1.970 |
Why?
|
| Coronary Disease | 36 | 2015 | 5989 | 1.840 |
Why?
|
| Middle Aged | 195 | 2024 | 219628 | 1.650 |
Why?
|
| Calcinosis | 15 | 2022 | 1476 | 1.650 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 12 | 2012 | 638 | 1.610 |
Why?
|
| Humans | 372 | 2024 | 759098 | 1.580 |
Why?
|
| Male | 241 | 2024 | 358602 | 1.540 |
Why?
|
| Graft Occlusion, Vascular | 7 | 2017 | 555 | 1.480 |
Why?
|
| Antithrombins | 9 | 2021 | 313 | 1.460 |
Why?
|
| Fibrosis | 20 | 2024 | 2038 | 1.440 |
Why?
|
| Aged | 146 | 2024 | 168615 | 1.400 |
Why?
|
| Atherosclerosis | 9 | 2024 | 3525 | 1.380 |
Why?
|
| Platelet Aggregation Inhibitors | 15 | 2021 | 3193 | 1.350 |
Why?
|
| Female | 216 | 2024 | 390174 | 1.310 |
Why?
|
| Angioscopy | 7 | 2015 | 48 | 1.300 |
Why?
|
| Creatine Kinase, MB Form | 6 | 2016 | 211 | 1.240 |
Why?
|
| Angina Pectoris | 12 | 2012 | 970 | 1.230 |
Why?
|
| Registries | 25 | 2021 | 8435 | 1.220 |
Why?
|
| Angina, Unstable | 13 | 2020 | 926 | 1.220 |
Why?
|
| Treatment Outcome | 77 | 2024 | 64867 | 1.180 |
Why?
|
| Diabetic Angiopathies | 4 | 2015 | 822 | 1.150 |
Why?
|
| Cardiovascular Agents | 8 | 2017 | 865 | 1.120 |
Why?
|
| Diabetes Mellitus | 7 | 2024 | 5875 | 1.070 |
Why?
|
| Chi-Square Distribution | 16 | 2017 | 3469 | 1.070 |
Why?
|
| Arginine | 24 | 2010 | 934 | 1.040 |
Why?
|
| Tunica Intima | 11 | 2013 | 455 | 1.030 |
Why?
|
| Time Factors | 53 | 2024 | 40083 | 1.010 |
Why?
|
| Thrombin | 7 | 2010 | 593 | 1.010 |
Why?
|
| Neovascularization, Pathologic | 6 | 2016 | 2635 | 0.970 |
Why?
|
| Myocardial Revascularization | 6 | 2020 | 841 | 0.940 |
Why?
|
| Models, Cardiovascular | 5 | 2021 | 974 | 0.910 |
Why?
|
| Mammary Arteries | 1 | 2024 | 81 | 0.910 |
Why?
|
| Retrospective Studies | 57 | 2024 | 80125 | 0.900 |
Why?
|
| Cholesterol, LDL | 5 | 2020 | 2417 | 0.880 |
Why?
|
| Endothelium, Vascular | 7 | 2021 | 4423 | 0.870 |
Why?
|
| Lysophospholipids | 7 | 2010 | 339 | 0.850 |
Why?
|
| Tyrosine | 8 | 2004 | 1440 | 0.830 |
Why?
|
| Inflammation | 18 | 2024 | 10746 | 0.820 |
Why?
|
| Fractional Flow Reserve, Myocardial | 2 | 2018 | 331 | 0.820 |
Why?
|
| Serpins | 1 | 2024 | 245 | 0.810 |
Why?
|
| Hirudins | 7 | 2015 | 194 | 0.810 |
Why?
|
| Electrocardiography | 15 | 2019 | 6400 | 0.770 |
Why?
|
| Hyperplasia | 7 | 2014 | 1157 | 0.730 |
Why?
|
| Thrombectomy | 5 | 2017 | 707 | 0.730 |
Why?
|
| Adenosine | 3 | 2017 | 832 | 0.720 |
Why?
|
| Blood Platelets | 10 | 2021 | 2522 | 0.720 |
Why?
|
| Phenotype | 12 | 2024 | 16524 | 0.720 |
Why?
|
| Risk Factors | 41 | 2024 | 74167 | 0.710 |
Why?
|
| Adipose Tissue | 4 | 2024 | 3291 | 0.700 |
Why?
|
| Troponin I | 4 | 2008 | 634 | 0.690 |
Why?
|
| Sulfonamides | 24 | 2010 | 1972 | 0.680 |
Why?
|
| Fibroblasts | 15 | 2018 | 4085 | 0.670 |
Why?
|
| No-Reflow Phenomenon | 2 | 2016 | 17 | 0.660 |
Why?
|
| Prognosis | 24 | 2024 | 29559 | 0.650 |
Why?
|
| Platelet Factor 4 | 4 | 2007 | 129 | 0.650 |
Why?
|
| Hemodynamics | 10 | 2022 | 4164 | 0.640 |
Why?
|
| Tomography | 6 | 2003 | 412 | 0.640 |
Why?
|
| Acceleration | 1 | 2019 | 189 | 0.630 |
Why?
|
| Image Interpretation, Computer-Assisted | 11 | 2017 | 3334 | 0.620 |
Why?
|
| Cyclic AMP | 4 | 2006 | 1456 | 0.610 |
Why?
|
| Deoxyadenosines | 1 | 2017 | 27 | 0.610 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2017 | 14 | 0.610 |
Why?
|
| Prosthesis Failure | 4 | 2018 | 1207 | 0.600 |
Why?
|
| Benzenesulfonates | 3 | 2008 | 165 | 0.600 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2017 | 46 | 0.600 |
Why?
|
| Thrombolytic Therapy | 12 | 2013 | 2106 | 0.590 |
Why?
|
| Heart Rupture, Post-Infarction | 2 | 2016 | 48 | 0.590 |
Why?
|
| Follow-Up Studies | 31 | 2021 | 39213 | 0.580 |
Why?
|
| Peptide Fragments | 6 | 2015 | 5100 | 0.580 |
Why?
|
| Stress, Mechanical | 6 | 2022 | 1665 | 0.570 |
Why?
|
| Coronary Artery Bypass | 8 | 2018 | 2274 | 0.560 |
Why?
|
| Myocardial Reperfusion | 6 | 2008 | 347 | 0.560 |
Why?
|
| Saphenous Vein | 2 | 2014 | 538 | 0.560 |
Why?
|
| Tissue Plasminogen Activator | 13 | 2000 | 1188 | 0.550 |
Why?
|
| Panax | 1 | 2016 | 28 | 0.550 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2016 | 75 | 0.550 |
Why?
|
| Integrin alpha5beta1 | 1 | 2016 | 37 | 0.540 |
Why?
|
| Coronary Aneurysm | 2 | 2011 | 233 | 0.540 |
Why?
|
| Plant Extracts | 2 | 2017 | 494 | 0.530 |
Why?
|
| Polyglactin 910 | 1 | 2016 | 55 | 0.520 |
Why?
|
| Heart Transplantation | 4 | 2012 | 3095 | 0.520 |
Why?
|
| Vascular Resistance | 1 | 2019 | 932 | 0.520 |
Why?
|
| Drug Therapy, Combination | 14 | 2021 | 6490 | 0.520 |
Why?
|
| Observer Variation | 12 | 2017 | 2596 | 0.520 |
Why?
|
| Paclitaxel | 3 | 2013 | 1716 | 0.520 |
Why?
|
| Ventricular Function, Left | 6 | 2008 | 3854 | 0.510 |
Why?
|
| Prosthesis Design | 9 | 2017 | 2123 | 0.500 |
Why?
|
| Myocardial Ischemia | 8 | 2017 | 2162 | 0.500 |
Why?
|
| Hemorrhage | 12 | 2015 | 3606 | 0.500 |
Why?
|
| Reproducibility of Results | 25 | 2020 | 20027 | 0.490 |
Why?
|
| Apoptosis | 8 | 2017 | 9470 | 0.490 |
Why?
|
| Algorithms | 11 | 2021 | 13951 | 0.480 |
Why?
|
| Imaging, Three-Dimensional | 7 | 2023 | 4041 | 0.480 |
Why?
|
| Image Enhancement | 6 | 2023 | 2878 | 0.470 |
Why?
|
| Football | 2 | 2019 | 502 | 0.470 |
Why?
|
| Seasons | 1 | 2020 | 1523 | 0.460 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2017 | 2267 | 0.460 |
Why?
|
| Risk Assessment | 23 | 2021 | 24049 | 0.460 |
Why?
|
| Hydrodynamics | 3 | 2021 | 167 | 0.450 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2015 | 165 | 0.450 |
Why?
|
| Phospholipases A2 | 1 | 2014 | 197 | 0.450 |
Why?
|
| Severity of Illness Index | 19 | 2024 | 15815 | 0.440 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2014 | 129 | 0.440 |
Why?
|
| Hypercholesterolemia | 1 | 2020 | 1155 | 0.440 |
Why?
|
| Recombinant Proteins | 14 | 2015 | 6538 | 0.430 |
Why?
|
| Incidence | 15 | 2020 | 21344 | 0.430 |
Why?
|
| Tomography, X-Ray Computed | 22 | 2024 | 20461 | 0.430 |
Why?
|
| Vasa Vasorum | 1 | 2012 | 25 | 0.430 |
Why?
|
| Alzheimer Disease | 3 | 2024 | 8539 | 0.420 |
Why?
|
| Athletes | 2 | 2019 | 1117 | 0.410 |
Why?
|
| Odds Ratio | 12 | 2017 | 9712 | 0.410 |
Why?
|
| Lipid Metabolism | 5 | 2017 | 1902 | 0.410 |
Why?
|
| Heart Injuries | 1 | 2014 | 208 | 0.400 |
Why?
|
| Contrast Media | 11 | 2012 | 5305 | 0.400 |
Why?
|
| Sex Characteristics | 4 | 2023 | 2627 | 0.400 |
Why?
|
| Prospective Studies | 30 | 2019 | 54190 | 0.390 |
Why?
|
| Arteriosclerosis | 7 | 2003 | 1052 | 0.390 |
Why?
|
| Vascular System Injuries | 1 | 2015 | 247 | 0.390 |
Why?
|
| Spectroscopy, Near-Infrared | 3 | 2014 | 742 | 0.390 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 5 | 2015 | 1217 | 0.380 |
Why?
|
| Disease Progression | 12 | 2021 | 13470 | 0.380 |
Why?
|
| Wound Healing | 5 | 2017 | 2781 | 0.370 |
Why?
|
| Hypolipidemic Agents | 1 | 2015 | 626 | 0.370 |
Why?
|
| Glomerular Filtration Rate | 2 | 2017 | 2161 | 0.370 |
Why?
|
| Macrophages | 10 | 2020 | 5723 | 0.370 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2013 | 320 | 0.360 |
Why?
|
| Heptanoic Acids | 1 | 2012 | 347 | 0.360 |
Why?
|
| Microcirculation | 4 | 2016 | 1276 | 0.360 |
Why?
|
| MAP Kinase Signaling System | 1 | 2017 | 1483 | 0.360 |
Why?
|
| Image Processing, Computer-Assisted | 11 | 2023 | 8936 | 0.360 |
Why?
|
| Amyloid beta-Peptides | 1 | 2024 | 3824 | 0.360 |
Why?
|
| Sensitivity and Specificity | 21 | 2015 | 14648 | 0.350 |
Why?
|
| Preoperative Care | 3 | 2019 | 2256 | 0.350 |
Why?
|
| Antibodies | 3 | 2007 | 2416 | 0.350 |
Why?
|
| Logistic Models | 9 | 2020 | 13309 | 0.340 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2013 | 380 | 0.340 |
Why?
|
| Prevalence | 10 | 2020 | 15639 | 0.340 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 4 | 2008 | 1059 | 0.340 |
Why?
|
| Blood Coagulation Tests | 3 | 2009 | 270 | 0.330 |
Why?
|
| Students | 1 | 2019 | 1718 | 0.330 |
Why?
|
| Homocysteine | 2 | 2022 | 640 | 0.330 |
Why?
|
| Aspirin | 6 | 2017 | 3359 | 0.330 |
Why?
|
| Fibrinogen | 2 | 2022 | 886 | 0.320 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2019 | 10825 | 0.320 |
Why?
|
| Cholesterol | 4 | 2023 | 2922 | 0.320 |
Why?
|
| Massachusetts | 7 | 2020 | 8788 | 0.320 |
Why?
|
| China | 4 | 2017 | 2349 | 0.320 |
Why?
|
| Japan | 3 | 2020 | 1367 | 0.320 |
Why?
|
| Multivariate Analysis | 7 | 2016 | 12152 | 0.320 |
Why?
|
| Oscillometry | 1 | 2009 | 145 | 0.320 |
Why?
|
| Microvessels | 3 | 2020 | 572 | 0.310 |
Why?
|
| Postoperative Complications | 8 | 2015 | 15662 | 0.310 |
Why?
|
| Hirudin Therapy | 3 | 2003 | 43 | 0.310 |
Why?
|
| Endovascular Procedures | 3 | 2018 | 2136 | 0.310 |
Why?
|
| Factor Xa | 1 | 2009 | 168 | 0.300 |
Why?
|
| Piperazines | 3 | 2008 | 2516 | 0.300 |
Why?
|
| Muscle, Smooth, Vascular | 3 | 2013 | 1481 | 0.300 |
Why?
|
| Stroke Volume | 7 | 2008 | 5496 | 0.300 |
Why?
|
| Aged, 80 and over | 27 | 2021 | 58864 | 0.300 |
Why?
|
| Leukocyte Count | 2 | 2008 | 1599 | 0.290 |
Why?
|
| Smoking | 2 | 2015 | 9066 | 0.290 |
Why?
|
| Renal Insufficiency | 3 | 2010 | 813 | 0.290 |
Why?
|
| Constriction, Pathologic | 2 | 2021 | 1101 | 0.290 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 625 | 0.290 |
Why?
|
| Acute Disease | 15 | 2019 | 7247 | 0.290 |
Why?
|
| Equipment Design | 6 | 2014 | 3529 | 0.290 |
Why?
|
| Diploidy | 6 | 2010 | 132 | 0.280 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 1798 | 0.280 |
Why?
|
| Creatinine | 4 | 2022 | 1904 | 0.280 |
Why?
|
| Health Status Disparities | 1 | 2018 | 1818 | 0.280 |
Why?
|
| Fish Diseases | 3 | 2011 | 37 | 0.280 |
Why?
|
| Postoperative Care | 2 | 2010 | 1476 | 0.270 |
Why?
|
| Health Services for the Aged | 1 | 2009 | 259 | 0.270 |
Why?
|
| Angioplasty | 2 | 2008 | 361 | 0.270 |
Why?
|
| Peripheral Arterial Disease | 1 | 2017 | 1310 | 0.270 |
Why?
|
| Pyrroles | 1 | 2012 | 1135 | 0.270 |
Why?
|
| Carotid Artery Diseases | 1 | 2012 | 881 | 0.260 |
Why?
|
| Rupture | 3 | 2013 | 441 | 0.260 |
Why?
|
| Telomere | 1 | 2012 | 934 | 0.260 |
Why?
|
| Single-Blind Method | 5 | 2016 | 1574 | 0.260 |
Why?
|
| Recurrence | 15 | 2019 | 8465 | 0.260 |
Why?
|
| Caveolin 1 | 6 | 2016 | 257 | 0.260 |
Why?
|
| Myoglobin | 1 | 2005 | 159 | 0.250 |
Why?
|
| Adult | 37 | 2021 | 219353 | 0.250 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2008 | 516 | 0.250 |
Why?
|
| Linear Models | 5 | 2017 | 5876 | 0.250 |
Why?
|
| Atherectomy, Coronary | 2 | 1995 | 146 | 0.250 |
Why?
|
| Muscle Cells | 1 | 2005 | 195 | 0.240 |
Why?
|
| Leukocytes | 2 | 2012 | 2030 | 0.240 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2009 | 537 | 0.240 |
Why?
|
| Iohexol | 4 | 2003 | 198 | 0.240 |
Why?
|
| Diagnostic Imaging | 4 | 2015 | 3526 | 0.230 |
Why?
|
| Pulmonary Veins | 1 | 2010 | 743 | 0.230 |
Why?
|
| Immunosuppressive Agents | 8 | 2015 | 4099 | 0.230 |
Why?
|
| Blood Coagulation | 4 | 2011 | 1152 | 0.230 |
Why?
|
| Kidney | 2 | 2017 | 7028 | 0.230 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2010 | 3617 | 0.220 |
Why?
|
| ROC Curve | 6 | 2016 | 3569 | 0.220 |
Why?
|
| Optics and Photonics | 2 | 2002 | 305 | 0.220 |
Why?
|
| Computer Simulation | 3 | 2018 | 6195 | 0.210 |
Why?
|
| Free Radical Scavengers | 1 | 2003 | 210 | 0.210 |
Why?
|
| Signal Transduction | 13 | 2019 | 23328 | 0.210 |
Why?
|
| Drug Monitoring | 1 | 2009 | 966 | 0.210 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 15726 | 0.210 |
Why?
|
| Republic of Korea | 2 | 2015 | 566 | 0.210 |
Why?
|
| Interleukin-6 | 2 | 2022 | 3201 | 0.200 |
Why?
|
| Second Messenger Systems | 1 | 2003 | 201 | 0.200 |
Why?
|
| Acetylcysteine | 1 | 2003 | 264 | 0.200 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 3216 | 0.200 |
Why?
|
| Animals | 52 | 2019 | 167531 | 0.200 |
Why?
|
| Prothrombin | 1 | 2022 | 191 | 0.200 |
Why?
|
| Autophagy | 4 | 2017 | 1336 | 0.200 |
Why?
|
| Myocardium | 5 | 2016 | 4676 | 0.200 |
Why?
|
| Aging | 7 | 2021 | 8633 | 0.200 |
Why?
|
| Endosonography | 2 | 2003 | 604 | 0.200 |
Why?
|
| Pulmonary Artery | 1 | 2010 | 1910 | 0.190 |
Why?
|
| Echocardiography | 9 | 2021 | 4970 | 0.190 |
Why?
|
| Statistics, Nonparametric | 4 | 2013 | 2852 | 0.190 |
Why?
|
| Hyperglycemia | 1 | 2010 | 1376 | 0.190 |
Why?
|
| Reperfusion | 2 | 2000 | 269 | 0.190 |
Why?
|
| Hemostasis, Surgical | 1 | 2001 | 129 | 0.190 |
Why?
|
| Up-Regulation | 7 | 2018 | 4123 | 0.180 |
Why?
|
| Salvage Therapy | 1 | 2007 | 1265 | 0.180 |
Why?
|
| C-Reactive Protein | 3 | 2022 | 3822 | 0.180 |
Why?
|
| Down-Regulation | 5 | 2009 | 2914 | 0.180 |
Why?
|
| Bile Acids and Salts | 1 | 2022 | 380 | 0.180 |
Why?
|
| Radiography | 5 | 2014 | 6964 | 0.180 |
Why?
|
| Caveolins | 4 | 2004 | 102 | 0.180 |
Why?
|
| Thromboembolism | 1 | 2007 | 1011 | 0.180 |
Why?
|
| Catheterization | 3 | 2007 | 1432 | 0.180 |
Why?
|
| Whole Blood Coagulation Time | 2 | 2011 | 31 | 0.180 |
Why?
|
| Diagnosis, Differential | 5 | 2017 | 12963 | 0.170 |
Why?
|
| Swine, Miniature | 2 | 2013 | 953 | 0.170 |
Why?
|
| AMP-Activated Protein Kinases | 3 | 2014 | 600 | 0.170 |
Why?
|
| Crystallization | 2 | 2017 | 534 | 0.170 |
Why?
|
| Hospitals, University | 2 | 2016 | 568 | 0.170 |
Why?
|
| Medical Records | 1 | 2005 | 1405 | 0.170 |
Why?
|
| Platelet Count | 3 | 2007 | 776 | 0.170 |
Why?
|
| Hypertension, Pulmonary | 1 | 2010 | 1567 | 0.160 |
Why?
|
| Tomography, Spiral Computed | 3 | 2006 | 273 | 0.160 |
Why?
|
| Heart Diseases | 2 | 2011 | 2799 | 0.160 |
Why?
|
| Platelet Aggregation | 7 | 2003 | 800 | 0.160 |
Why?
|
| Propensity Score | 2 | 2017 | 1917 | 0.160 |
Why?
|
| Amyloid | 1 | 2024 | 839 | 0.160 |
Why?
|
| Coronary Care Units | 1 | 2000 | 235 | 0.160 |
Why?
|
| Endocytosis | 2 | 2004 | 960 | 0.160 |
Why?
|
| Rabbits | 7 | 2012 | 4772 | 0.160 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 1003 | 0.160 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2017 | 444 | 0.150 |
Why?
|
| Platelet-Rich Plasma | 1 | 2021 | 179 | 0.150 |
Why?
|
| Comorbidity | 5 | 2020 | 10550 | 0.150 |
Why?
|
| Brain Concussion | 2 | 2019 | 1387 | 0.150 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 14439 | 0.150 |
Why?
|
| Sex Factors | 4 | 2020 | 10515 | 0.150 |
Why?
|
| Scutellaria baicalensis | 1 | 2017 | 4 | 0.150 |
Why?
|
| Quercetin | 1 | 2018 | 97 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2024 | 36164 | 0.150 |
Why?
|
| Thermography | 2 | 2011 | 63 | 0.150 |
Why?
|
| Metals | 2 | 2013 | 730 | 0.150 |
Why?
|
| Partial Thromboplastin Time | 3 | 2007 | 206 | 0.140 |
Why?
|
| Femoral Artery | 7 | 2000 | 837 | 0.140 |
Why?
|
| YY1 Transcription Factor | 1 | 2017 | 59 | 0.140 |
Why?
|
| Proteomics | 3 | 2024 | 3803 | 0.140 |
Why?
|
| Phantoms, Imaging | 3 | 2023 | 2508 | 0.140 |
Why?
|
| Atrophy | 1 | 2022 | 1625 | 0.140 |
Why?
|
| Necrosis | 2 | 2015 | 1613 | 0.140 |
Why?
|
| Brain | 2 | 2024 | 26860 | 0.140 |
Why?
|
| Swine | 7 | 2013 | 5895 | 0.140 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2017 | 282 | 0.140 |
Why?
|
| Treatment Failure | 3 | 2017 | 2641 | 0.130 |
Why?
|
| Pilot Projects | 3 | 2018 | 8530 | 0.130 |
Why?
|
| Age Factors | 8 | 2020 | 18391 | 0.130 |
Why?
|
| Calcium | 3 | 2005 | 5718 | 0.130 |
Why?
|
| Probability | 3 | 2007 | 2474 | 0.130 |
Why?
|
| Caspase 8 | 1 | 2016 | 188 | 0.130 |
Why?
|
| Asia | 1 | 2017 | 617 | 0.130 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 3 | 2008 | 482 | 0.130 |
Why?
|
| Neutrophils | 1 | 2008 | 3767 | 0.130 |
Why?
|
| Emergency Medicine | 1 | 2005 | 1195 | 0.130 |
Why?
|
| Cholesterol, HDL | 1 | 2022 | 1816 | 0.130 |
Why?
|
| Acute Kidney Injury | 2 | 2009 | 1916 | 0.130 |
Why?
|
| Cohort Studies | 7 | 2019 | 41266 | 0.130 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2005 | 1425 | 0.130 |
Why?
|
| Cystatin C | 1 | 2017 | 268 | 0.130 |
Why?
|
| Phosphorylation | 5 | 2017 | 8312 | 0.130 |
Why?
|
| Suction | 1 | 2016 | 264 | 0.130 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2003 | 1244 | 0.130 |
Why?
|
| Disease-Free Survival | 3 | 2017 | 6814 | 0.130 |
Why?
|
| Cell Proliferation | 7 | 2013 | 10427 | 0.130 |
Why?
|
| Heart | 3 | 2024 | 4391 | 0.130 |
Why?
|
| Chest Pain | 3 | 2020 | 1106 | 0.120 |
Why?
|
| Metoprolol | 3 | 1990 | 92 | 0.120 |
Why?
|
| Lymphocyte Activation | 2 | 2003 | 5423 | 0.120 |
Why?
|
| Amidines | 1 | 2014 | 29 | 0.120 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2003 | 2524 | 0.120 |
Why?
|
| Area Under Curve | 2 | 2016 | 1634 | 0.120 |
Why?
|
| Antigens, Differentiation | 1 | 2017 | 849 | 0.120 |
Why?
|
| Placenta | 1 | 2024 | 1699 | 0.120 |
Why?
|
| Receptors, Lysophosphatidic Acid | 2 | 2006 | 77 | 0.120 |
Why?
|
| Cell Line, Tumor | 5 | 2018 | 16878 | 0.120 |
Why?
|
| Dermatan Sulfate | 2 | 2007 | 43 | 0.120 |
Why?
|
| Body Mass Index | 3 | 2007 | 12871 | 0.120 |
Why?
|
| Disease Models, Animal | 9 | 2014 | 18094 | 0.120 |
Why?
|
| Membranes, Artificial | 1 | 2016 | 367 | 0.120 |
Why?
|
| Feasibility Studies | 5 | 2012 | 5192 | 0.110 |
Why?
|
| Chondroitin Sulfates | 2 | 2007 | 175 | 0.110 |
Why?
|
| Coronary Vasospasm | 1 | 1994 | 83 | 0.110 |
Why?
|
| Retreatment | 3 | 2015 | 599 | 0.110 |
Why?
|
| Coronary Occlusion | 1 | 2017 | 308 | 0.110 |
Why?
|
| Plasminogen Activators | 4 | 2000 | 199 | 0.110 |
Why?
|
| Equipment Safety | 1 | 2014 | 258 | 0.110 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2014 | 186 | 0.110 |
Why?
|
| Computational Biology | 2 | 2018 | 3505 | 0.110 |
Why?
|
| Dibenzocycloheptenes | 1 | 2013 | 27 | 0.110 |
Why?
|
| Rotenone | 1 | 2013 | 45 | 0.110 |
Why?
|
| Regional Blood Flow | 2 | 2014 | 1489 | 0.110 |
Why?
|
| Europe | 1 | 2020 | 3427 | 0.110 |
Why?
|
| Head | 1 | 2019 | 921 | 0.110 |
Why?
|
| Colorimetry | 1 | 2014 | 153 | 0.110 |
Why?
|
| Gelsolin | 2 | 2003 | 189 | 0.110 |
Why?
|
| Troponin T | 2 | 2008 | 774 | 0.110 |
Why?
|
| Cell Survival | 4 | 2017 | 5793 | 0.110 |
Why?
|
| Resorcinols | 1 | 2013 | 41 | 0.110 |
Why?
|
| Weightlessness | 1 | 2014 | 101 | 0.110 |
Why?
|
| Enzyme Inhibitors | 4 | 2014 | 3722 | 0.110 |
Why?
|
| Heparitin Sulfate | 2 | 2007 | 224 | 0.110 |
Why?
|
| Clinical Trials as Topic | 6 | 2010 | 8050 | 0.110 |
Why?
|
| HEK293 Cells | 3 | 2017 | 4263 | 0.110 |
Why?
|
| Emergency Service, Hospital | 4 | 2009 | 7788 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 6530 | 0.100 |
Why?
|
| Mitral Valve Stenosis | 1 | 1995 | 347 | 0.100 |
Why?
|
| Replication Protein A | 1 | 2012 | 52 | 0.100 |
Why?
|
| Vasculitis | 2 | 1993 | 524 | 0.100 |
Why?
|
| Body Weight | 2 | 2010 | 4606 | 0.100 |
Why?
|
| Obesity | 2 | 2007 | 12896 | 0.100 |
Why?
|
| Bass | 1 | 2011 | 7 | 0.100 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 25853 | 0.100 |
Why?
|
| Survival Rate | 7 | 2007 | 12793 | 0.100 |
Why?
|
| Equipment Failure | 2 | 2006 | 577 | 0.100 |
Why?
|
| Immunity, Cellular | 2 | 2012 | 1543 | 0.100 |
Why?
|
| Polytetrafluoroethylene | 1 | 2013 | 245 | 0.100 |
Why?
|
| Australia | 1 | 2015 | 1287 | 0.100 |
Why?
|
| Carotid Artery, Common | 1 | 2012 | 177 | 0.100 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2013 | 612 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 13243 | 0.100 |
Why?
|
| Platelet Membrane Glycoproteins | 4 | 1994 | 285 | 0.100 |
Why?
|
| Artifacts | 3 | 2023 | 1894 | 0.100 |
Why?
|
| Vibrio Infections | 1 | 2011 | 33 | 0.100 |
Why?
|
| Vibrio | 1 | 2011 | 43 | 0.100 |
Why?
|
| Cells, Cultured | 11 | 2018 | 18937 | 0.100 |
Why?
|
| Membrane Proteins | 4 | 2013 | 7838 | 0.100 |
Why?
|
| Mice, Nude | 1 | 2017 | 3602 | 0.090 |
Why?
|
| Alcoholic Beverages | 1 | 2012 | 264 | 0.090 |
Why?
|
| Cisplatin | 1 | 2017 | 1643 | 0.090 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2008 | 2128 | 0.090 |
Why?
|
| Survival Analysis | 4 | 2016 | 10181 | 0.090 |
Why?
|
| Cadaver | 3 | 2016 | 1342 | 0.090 |
Why?
|
| Surface Properties | 2 | 2011 | 1156 | 0.090 |
Why?
|
| Thromboplastin | 1 | 1992 | 286 | 0.090 |
Why?
|
| Porosity | 1 | 2011 | 349 | 0.090 |
Why?
|
| Schools | 1 | 2019 | 1473 | 0.090 |
Why?
|
| Hospitals, General | 1 | 2015 | 795 | 0.090 |
Why?
|
| Device Approval | 1 | 2012 | 164 | 0.090 |
Why?
|
| Aeromonas hydrophila | 1 | 2009 | 10 | 0.090 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2010 | 78 | 0.090 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2017 | 1132 | 0.090 |
Why?
|
| Interferon Regulatory Factor-2 | 1 | 2009 | 22 | 0.090 |
Why?
|
| Goldfish | 1 | 2009 | 65 | 0.090 |
Why?
|
| Antioxidants | 1 | 2018 | 1666 | 0.090 |
Why?
|
| Cathepsin K | 1 | 2009 | 65 | 0.090 |
Why?
|
| Carotid Stenosis | 2 | 2008 | 872 | 0.090 |
Why?
|
| Caveolae | 1 | 2010 | 55 | 0.090 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2009 | 68 | 0.090 |
Why?
|
| Double-Blind Method | 4 | 2008 | 12383 | 0.090 |
Why?
|
| Cell Movement | 3 | 2017 | 5196 | 0.080 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 1 | 2009 | 68 | 0.080 |
Why?
|
| United States | 6 | 2020 | 72238 | 0.080 |
Why?
|
| Platelet Activation | 3 | 2000 | 661 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 2 | 2017 | 6143 | 0.080 |
Why?
|
| Stress, Physiological | 1 | 2017 | 1395 | 0.080 |
Why?
|
| Alginates | 1 | 2010 | 247 | 0.080 |
Why?
|
| RNA, Small Interfering | 5 | 2014 | 3443 | 0.080 |
Why?
|
| Angioplasty, Balloon | 2 | 2007 | 599 | 0.080 |
Why?
|
| Circadian Rhythm | 1 | 2021 | 2567 | 0.080 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 1738 | 0.080 |
Why?
|
| Hippocampus | 1 | 2022 | 3726 | 0.080 |
Why?
|
| Athletic Injuries | 1 | 2019 | 1194 | 0.080 |
Why?
|
| Immunity, Innate | 2 | 2012 | 3045 | 0.080 |
Why?
|
| Peptides | 3 | 2012 | 4325 | 0.080 |
Why?
|
| Arterial Occlusive Diseases | 2 | 1991 | 752 | 0.080 |
Why?
|
| Adolescent | 7 | 2019 | 87551 | 0.080 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2011 | 234 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2018 | 2925 | 0.080 |
Why?
|
| NF-kappa B | 1 | 2017 | 2486 | 0.080 |
Why?
|
| Anticholesteremic Agents | 1 | 2016 | 987 | 0.080 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2015 | 1192 | 0.080 |
Why?
|
| Nitric Oxide | 1 | 2017 | 2141 | 0.080 |
Why?
|
| Ferritins | 1 | 2011 | 599 | 0.080 |
Why?
|
| Blood Flow Velocity | 2 | 2003 | 1371 | 0.080 |
Why?
|
| Patient Selection | 3 | 2010 | 4268 | 0.080 |
Why?
|
| Terminology as Topic | 2 | 2014 | 1534 | 0.080 |
Why?
|
| T-Lymphocytes | 2 | 2003 | 10069 | 0.080 |
Why?
|
| Gluconeogenesis | 1 | 2009 | 185 | 0.080 |
Why?
|
| Orchiectomy | 1 | 2010 | 470 | 0.080 |
Why?
|
| Endoplasmic Reticulum | 1 | 2014 | 1135 | 0.080 |
Why?
|
| Proteins | 1 | 2003 | 6024 | 0.080 |
Why?
|
| Gene Expression | 3 | 2018 | 7583 | 0.080 |
Why?
|
| Young Adult | 4 | 2017 | 58477 | 0.080 |
Why?
|
| Bleeding Time | 3 | 2000 | 84 | 0.080 |
Why?
|
| Dogs | 11 | 1994 | 3839 | 0.070 |
Why?
|
| Liver | 2 | 2014 | 7514 | 0.070 |
Why?
|
| Materials Testing | 1 | 2011 | 855 | 0.070 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2009 | 238 | 0.070 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2009 | 345 | 0.070 |
Why?
|
| Models, Biological | 5 | 2017 | 9460 | 0.070 |
Why?
|
| Salmonella typhimurium | 1 | 2010 | 341 | 0.070 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2019 | 2772 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2024 | 6436 | 0.070 |
Why?
|
| Shock, Cardiogenic | 2 | 2009 | 731 | 0.070 |
Why?
|
| Angiography | 2 | 1990 | 1608 | 0.070 |
Why?
|
| Biocompatible Materials | 1 | 2016 | 1688 | 0.070 |
Why?
|
| Drug Combinations | 3 | 2000 | 2021 | 0.070 |
Why?
|
| Infusions, Intravenous | 3 | 2007 | 2234 | 0.070 |
Why?
|
| Immunoglobulin Fab Fragments | 3 | 2000 | 465 | 0.070 |
Why?
|
| Drug Carriers | 1 | 2011 | 705 | 0.070 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase RIalpha Subunit | 1 | 2006 | 24 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 5 | 2000 | 9131 | 0.070 |
Why?
|
| Hospital Mortality | 3 | 2010 | 5414 | 0.070 |
Why?
|
| Ticlopidine | 1 | 2012 | 895 | 0.070 |
Why?
|
| Heart Function Tests | 1 | 2007 | 318 | 0.070 |
Why?
|
| Nanostructures | 1 | 2011 | 547 | 0.070 |
Why?
|
| Adenine | 2 | 2010 | 976 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2010 | 6358 | 0.070 |
Why?
|
| Sclerosing Solutions | 1 | 2006 | 79 | 0.070 |
Why?
|
| Acetophenones | 1 | 2006 | 53 | 0.070 |
Why?
|
| Streptococcal Infections | 1 | 2010 | 616 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 5790 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 4356 | 0.070 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2011 | 390 | 0.070 |
Why?
|
| Benzopyrans | 1 | 2006 | 63 | 0.070 |
Why?
|
| Syndrome | 5 | 2006 | 3275 | 0.070 |
Why?
|
| Polymers | 2 | 2011 | 1618 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2007 | 613 | 0.060 |
Why?
|
| Radionuclide Imaging | 1 | 2010 | 1974 | 0.060 |
Why?
|
| Epinephrine | 1 | 2009 | 791 | 0.060 |
Why?
|
| Triiodobenzoic Acids | 5 | 2008 | 123 | 0.060 |
Why?
|
| Forecasting | 2 | 2008 | 2928 | 0.060 |
Why?
|
| Immune System | 1 | 2010 | 791 | 0.060 |
Why?
|
| Ultrasonography | 2 | 2010 | 5954 | 0.060 |
Why?
|
| Postoperative Hemorrhage | 1 | 2009 | 421 | 0.060 |
Why?
|
| Emergency Treatment | 1 | 2009 | 498 | 0.060 |
Why?
|
| Enoxaparin | 1 | 2007 | 397 | 0.060 |
Why?
|
| Rotation | 1 | 2007 | 514 | 0.060 |
Why?
|
| Multienzyme Complexes | 1 | 2008 | 666 | 0.060 |
Why?
|
| Mitosis | 1 | 2010 | 1195 | 0.060 |
Why?
|
| Cell Degranulation | 2 | 1996 | 278 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2017 | 2295 | 0.060 |
Why?
|
| Carbazoles | 1 | 2006 | 221 | 0.060 |
Why?
|
| Luciferases | 1 | 2006 | 717 | 0.060 |
Why?
|
| Reference Values | 2 | 2011 | 4914 | 0.060 |
Why?
|
| Carrier Proteins | 2 | 2012 | 4938 | 0.060 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2011 | 1429 | 0.060 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2006 | 490 | 0.060 |
Why?
|
| Catalytic Domain | 1 | 2006 | 706 | 0.060 |
Why?
|
| Aortic Aneurysm | 1 | 2008 | 646 | 0.060 |
Why?
|
| Ventricular Septal Rupture | 1 | 2003 | 17 | 0.060 |
Why?
|
| Insulin Resistance | 3 | 2014 | 3959 | 0.050 |
Why?
|
| Cell Line | 5 | 2012 | 15638 | 0.050 |
Why?
|
| Erythrocytes | 2 | 1991 | 2416 | 0.050 |
Why?
|
| Cell Nucleus | 2 | 2010 | 2912 | 0.050 |
Why?
|
| Echocardiography, Doppler | 1 | 2007 | 900 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2006 | 2897 | 0.050 |
Why?
|
| Proteome | 1 | 2013 | 1847 | 0.050 |
Why?
|
| Gene Expression Regulation | 4 | 2010 | 11903 | 0.050 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2003 | 198 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2009 | 2364 | 0.050 |
Why?
|
| Superoxide Dismutase | 2 | 2018 | 593 | 0.050 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2005 | 479 | 0.050 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2003 | 199 | 0.050 |
Why?
|
| World Health Organization | 1 | 2008 | 1317 | 0.050 |
Why?
|
| Triage | 1 | 2009 | 982 | 0.050 |
Why?
|
| Prolapse | 1 | 2001 | 63 | 0.050 |
Why?
|
| Heart Ventricles | 4 | 2006 | 3802 | 0.050 |
Why?
|
| Cell Cycle Proteins | 2 | 2006 | 3449 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2017 | 8001 | 0.050 |
Why?
|
| Pregnancy | 1 | 2024 | 29650 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2007 | 1823 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2005 | 818 | 0.050 |
Why?
|
| Thrombophilia | 2 | 2003 | 307 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2009 | 1972 | 0.050 |
Why?
|
| Microscopy | 1 | 2006 | 879 | 0.050 |
Why?
|
| Device Removal | 1 | 2006 | 635 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 8489 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2010 | 1583 | 0.050 |
Why?
|
| Spectrum Analysis | 1 | 2003 | 452 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 4313 | 0.050 |
Why?
|
| Fibrinolysis | 2 | 1997 | 332 | 0.050 |
Why?
|
| Sulfoxides | 1 | 2000 | 46 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2006 | 699 | 0.050 |
Why?
|
| Polysaccharides | 1 | 2007 | 1010 | 0.050 |
Why?
|
| Benzamidines | 1 | 2000 | 23 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2013 | 11046 | 0.050 |
Why?
|
| Models, Immunological | 1 | 2003 | 505 | 0.050 |
Why?
|
| Clathrin | 1 | 2002 | 257 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2007 | 4893 | 0.050 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 4312 | 0.050 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2004 | 290 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2008 | 12526 | 0.050 |
Why?
|
| Pulmonary Embolism | 2 | 2008 | 2537 | 0.040 |
Why?
|
| Embolism | 1 | 2003 | 408 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 4871 | 0.040 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2012 | 2016 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2009 | 1208 | 0.040 |
Why?
|
| Ethanol | 1 | 2006 | 1314 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2008 | 21992 | 0.040 |
Why?
|
| Anatomy, Cross-Sectional | 3 | 2007 | 141 | 0.040 |
Why?
|
| Cell Cycle | 3 | 2018 | 2936 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 2824 | 0.040 |
Why?
|
| Ancrod | 1 | 1999 | 7 | 0.040 |
Why?
|
| Fluid Therapy | 1 | 2003 | 592 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 9587 | 0.040 |
Why?
|
| Myocardial Contraction | 3 | 1990 | 1516 | 0.040 |
Why?
|
| Blood Vessels | 1 | 2005 | 1112 | 0.040 |
Why?
|
| Drug Evaluation | 1 | 2000 | 642 | 0.040 |
Why?
|
| Gangrene | 1 | 1999 | 92 | 0.040 |
Why?
|
| Diatrizoate | 3 | 1996 | 81 | 0.040 |
Why?
|
| Protein C | 1 | 1999 | 132 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 3793 | 0.040 |
Why?
|
| Acetates | 1 | 2000 | 322 | 0.040 |
Why?
|
| Oximes | 1 | 2000 | 306 | 0.040 |
Why?
|
| Parkinson Disease | 1 | 2013 | 2843 | 0.040 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2023 | 470 | 0.040 |
Why?
|
| Rats, Inbred F344 | 2 | 2010 | 806 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2000 | 817 | 0.040 |
Why?
|
| Creatine Kinase | 1 | 2000 | 691 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2000 | 336 | 0.040 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2003 | 1572 | 0.040 |
Why?
|
| Peptides, Cyclic | 1 | 2000 | 392 | 0.040 |
Why?
|
| Death | 1 | 2023 | 677 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 6 | 2014 | 21892 | 0.040 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2018 | 132 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2003 | 1695 | 0.040 |
Why?
|
| RNA Interference | 3 | 2014 | 2848 | 0.040 |
Why?
|
| Atherectomy | 1 | 1998 | 41 | 0.040 |
Why?
|
| Gene Silencing | 2 | 2018 | 1512 | 0.040 |
Why?
|
| Software | 1 | 2012 | 4421 | 0.040 |
Why?
|
| Catalase | 1 | 2018 | 216 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2006 | 4668 | 0.040 |
Why?
|
| Alanine | 1 | 2000 | 606 | 0.040 |
Why?
|
| Lipoprotein Lipase | 1 | 2018 | 134 | 0.040 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2000 | 661 | 0.040 |
Why?
|
| Indoles | 1 | 2006 | 1828 | 0.040 |
Why?
|
| alpha-2-Antiplasmin | 1 | 1997 | 13 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2013 | 12270 | 0.040 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2018 | 141 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2004 | 2416 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2017 | 12106 | 0.040 |
Why?
|
| Soccer | 1 | 2019 | 141 | 0.040 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2006 | 1284 | 0.040 |
Why?
|
| DNA, Complementary | 2 | 2011 | 1991 | 0.040 |
Why?
|
| Cause of Death | 1 | 2007 | 3719 | 0.030 |
Why?
|
| Reactive Oxygen Species | 2 | 2018 | 2134 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2005 | 2114 | 0.030 |
Why?
|
| Mice | 9 | 2014 | 80993 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 7379 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2001 | 2294 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2014 | 3604 | 0.030 |
Why?
|
| Ioxaglic Acid | 4 | 1996 | 29 | 0.030 |
Why?
|
| Injections, Intravenous | 3 | 2002 | 1384 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 8548 | 0.030 |
Why?
|
| Protein Transport | 2 | 2012 | 1967 | 0.030 |
Why?
|
| Age Distribution | 1 | 2001 | 2891 | 0.030 |
Why?
|
| Urokinase-Type Plasminogen Activator | 2 | 1987 | 326 | 0.030 |
Why?
|
| Light | 2 | 2016 | 1343 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 697 | 0.030 |
Why?
|
| Heart Rate | 1 | 2006 | 4165 | 0.030 |
Why?
|
| Scattering, Radiation | 1 | 2016 | 488 | 0.030 |
Why?
|
| Vitamin K 3 | 2 | 2003 | 14 | 0.030 |
Why?
|
| Fluoxetine | 1 | 2018 | 733 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 13625 | 0.030 |
Why?
|
| Epitopes | 1 | 2000 | 2501 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2014 | 451 | 0.030 |
Why?
|
| Transfection | 3 | 2009 | 5781 | 0.030 |
Why?
|
| Foam Cells | 1 | 1993 | 68 | 0.030 |
Why?
|
| Medicine, Korean Traditional | 1 | 2013 | 3 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2003 | 2821 | 0.030 |
Why?
|
| Vitis | 1 | 2013 | 19 | 0.030 |
Why?
|
| Embolization, Therapeutic | 1 | 2003 | 1412 | 0.030 |
Why?
|
| Organ Specificity | 2 | 2011 | 1948 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2014 | 390 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2009 | 8520 | 0.030 |
Why?
|
| Boston | 1 | 2005 | 9274 | 0.030 |
Why?
|
| Diet | 1 | 2010 | 8001 | 0.030 |
Why?
|
| Plants, Medicinal | 1 | 2013 | 164 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2000 | 4037 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2003 | 2218 | 0.030 |
Why?
|
| Neurotoxins | 1 | 2013 | 240 | 0.020 |
Why?
|
| Mice, Obese | 1 | 2012 | 420 | 0.020 |
Why?
|
| Cell Division | 2 | 2003 | 4445 | 0.020 |
Why?
|
| Piperidines | 1 | 2000 | 1648 | 0.020 |
Why?
|
| Diatomaceous Earth | 1 | 2011 | 5 | 0.020 |
Why?
|
| Kaolin | 1 | 2011 | 16 | 0.020 |
Why?
|
| Reoperation | 3 | 2013 | 4286 | 0.020 |
Why?
|
| Decision Making | 1 | 2005 | 3917 | 0.020 |
Why?
|
| Rats | 4 | 2010 | 23577 | 0.020 |
Why?
|
| Poly I-C | 1 | 2011 | 112 | 0.020 |
Why?
|
| Hemagglutination | 1 | 2010 | 32 | 0.020 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1996 | 623 | 0.020 |
Why?
|
| Base Sequence | 2 | 2013 | 12442 | 0.020 |
Why?
|
| Skin | 2 | 2018 | 4466 | 0.020 |
Why?
|
| Cineangiography | 1 | 1990 | 113 | 0.020 |
Why?
|
| Hexuronic Acids | 1 | 2010 | 145 | 0.020 |
Why?
|
| Glucuronic Acid | 1 | 2010 | 150 | 0.020 |
Why?
|
| Phytotherapy | 1 | 2013 | 293 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2000 | 2441 | 0.020 |
Why?
|
| Diatrizoate Meglumine | 1 | 1990 | 79 | 0.020 |
Why?
|
| Respiratory Burst | 1 | 2010 | 110 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2003 | 460 | 0.020 |
Why?
|
| Complement Pathway, Alternative | 1 | 2010 | 115 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1999 | 3518 | 0.020 |
Why?
|
| Muramidase | 1 | 2010 | 168 | 0.020 |
Why?
|
| Warfarin | 1 | 1999 | 1516 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 2 | 2011 | 2651 | 0.020 |
Why?
|
| Streptococcus | 1 | 2010 | 198 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2010 | 150 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2000 | 1892 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2017 | 1293 | 0.020 |
Why?
|
| Gene Expression Profiling | 3 | 2011 | 9372 | 0.020 |
Why?
|
| Injections, Intra-Arterial | 1 | 1990 | 182 | 0.020 |
Why?
|
| Dihydrotestosterone | 1 | 2010 | 195 | 0.020 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2011 | 192 | 0.020 |
Why?
|
| Aminoimidazole Carboxamide | 1 | 2010 | 85 | 0.020 |
Why?
|
| Ribonucleotides | 1 | 2010 | 114 | 0.020 |
Why?
|
| G-Protein-Coupled Receptor Kinase 3 | 1 | 2009 | 6 | 0.020 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2008 | 1108 | 0.020 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2009 | 9 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2006 | 5637 | 0.020 |
Why?
|
| Mice, Inbred DBA | 1 | 2010 | 612 | 0.020 |
Why?
|
| Karyopherins | 1 | 2010 | 131 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2003 | 3152 | 0.020 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2010 | 283 | 0.020 |
Why?
|
| Intracellular Space | 1 | 2010 | 197 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2002 | 4409 | 0.020 |
Why?
|
| Angiography, Digital Subtraction | 1 | 1990 | 334 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2019 | 3761 | 0.020 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1989 | 221 | 0.020 |
Why?
|
| Serum | 1 | 2010 | 212 | 0.020 |
Why?
|
| Angiocardiography | 1 | 1988 | 153 | 0.020 |
Why?
|
| Lipoproteins | 1 | 1993 | 883 | 0.020 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 2008 | 117 | 0.020 |
Why?
|
| Prefrontal Cortex | 1 | 2019 | 2210 | 0.020 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2009 | 108 | 0.020 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2009 | 213 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2011 | 813 | 0.020 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2008 | 173 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2009 | 673 | 0.020 |
Why?
|
| Methods | 1 | 1988 | 1074 | 0.020 |
Why?
|
| Blood Glucose | 2 | 2014 | 6366 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2011 | 1649 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 1618 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2012 | 724 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2013 | 1125 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2008 | 358 | 0.020 |
Why?
|
| S Phase | 1 | 2008 | 423 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 1 | 2010 | 907 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2011 | 2176 | 0.020 |
Why?
|
| Glucagon | 1 | 2009 | 531 | 0.020 |
Why?
|
| Calibration | 1 | 2009 | 816 | 0.020 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2010 | 542 | 0.020 |
Why?
|
| Protein Kinase C-alpha | 1 | 2006 | 113 | 0.020 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2010 | 700 | 0.020 |
Why?
|
| A Kinase Anchor Proteins | 1 | 2006 | 52 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2008 | 453 | 0.020 |
Why?
|
| Mitral Valve | 1 | 1995 | 1485 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2009 | 748 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2012 | 3107 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2010 | 1814 | 0.020 |
Why?
|
| Radiographic Image Enhancement | 1 | 2011 | 881 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2010 | 792 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 1993 | 1725 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2011 | 1078 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2013 | 2190 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 2056 | 0.020 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2010 | 855 | 0.020 |
Why?
|
| Injections, Intralesional | 1 | 2006 | 278 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2000 | 10329 | 0.020 |
Why?
|
| Drug Implants | 1 | 2006 | 230 | 0.020 |
Why?
|
| California | 1 | 2009 | 1403 | 0.020 |
Why?
|
| Actins | 2 | 2003 | 2049 | 0.020 |
Why?
|
| Foreign-Body Migration | 1 | 2007 | 218 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2010 | 1535 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 1986 | 436 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2014 | 12765 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2008 | 826 | 0.020 |
Why?
|
| Systole | 1 | 1987 | 947 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 2062 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1990 | 1253 | 0.010 |
Why?
|
| Carotid Arteries | 2 | 2002 | 951 | 0.010 |
Why?
|
| Biopsy | 1 | 2016 | 6770 | 0.010 |
Why?
|
| Monocytes | 1 | 1993 | 2568 | 0.010 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2004 | 119 | 0.010 |
Why?
|
| Lethal Dose 50 | 1 | 2003 | 72 | 0.010 |
Why?
|
| Lysosomes | 1 | 2009 | 917 | 0.010 |
Why?
|
| Focal Adhesions | 1 | 2004 | 115 | 0.010 |
Why?
|
| Phylogeny | 1 | 2011 | 2765 | 0.010 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2004 | 186 | 0.010 |
Why?
|
| Radiography, Interventional | 1 | 2011 | 1113 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 2214 | 0.010 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2004 | 187 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2012 | 2192 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 2004 | 574 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2009 | 2932 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 2013 | 1758 | 0.010 |
Why?
|
| Estradiol | 1 | 2010 | 1931 | 0.010 |
Why?
|
| Protein Binding | 2 | 2006 | 9334 | 0.010 |
Why?
|
| DNA Repair | 1 | 2012 | 2039 | 0.010 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2004 | 242 | 0.010 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2004 | 277 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 1655 | 0.010 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2010 | 1615 | 0.010 |
Why?
|
| Aorta | 2 | 2002 | 2041 | 0.010 |
Why?
|
| Cell Size | 1 | 2004 | 622 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2003 | 530 | 0.010 |
Why?
|
| Phospholipase D | 1 | 2002 | 67 | 0.010 |
Why?
|
| Heart Septum | 1 | 2003 | 303 | 0.010 |
Why?
|
| Phospholipase C gamma | 1 | 2002 | 130 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2004 | 956 | 0.010 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2002 | 178 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2017 | 9245 | 0.010 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2003 | 226 | 0.010 |
Why?
|
| Type C Phospholipases | 1 | 2002 | 287 | 0.010 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2003 | 282 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 2448 | 0.010 |
Why?
|
| Aortic Valve Stenosis | 1 | 1994 | 2066 | 0.010 |
Why?
|
| Infrared Rays | 1 | 2002 | 246 | 0.010 |
Why?
|
| Flow Cytometry | 3 | 1996 | 5841 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 2750 | 0.010 |
Why?
|
| Neoplasms | 1 | 2009 | 22023 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 2866 | 0.010 |
Why?
|
| Purpura | 1 | 2001 | 117 | 0.010 |
Why?
|
| Information Storage and Retrieval | 1 | 2006 | 821 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 2003 | 694 | 0.010 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2006 | 876 | 0.010 |
Why?
|
| Family Health | 1 | 2005 | 1258 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 4299 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 2000 | 91 | 0.010 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2002 | 617 | 0.010 |
Why?
|
| Integrins | 1 | 2004 | 840 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2002 | 1631 | 0.010 |
Why?
|
| Movement | 1 | 1986 | 1471 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2003 | 2557 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2000 | 120 | 0.010 |
Why?
|
| Species Specificity | 1 | 2003 | 2408 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2012 | 4721 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2004 | 1167 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2012 | 4523 | 0.010 |
Why?
|
| DNA | 2 | 2003 | 7235 | 0.010 |
Why?
|
| Dissection | 1 | 2000 | 298 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2005 | 1342 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2008 | 2630 | 0.010 |
Why?
|
| Phospholipids | 1 | 2002 | 788 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 1248 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 1149 | 0.010 |
Why?
|
| Stroke | 1 | 2020 | 9936 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 13439 | 0.010 |
Why?
|
| Cytokines | 1 | 2012 | 7290 | 0.010 |
Why?
|
| Arteries | 1 | 2003 | 1115 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2002 | 1690 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 3800 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 17611 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2003 | 1787 | 0.010 |
Why?
|
| Ferrets | 1 | 1997 | 176 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2000 | 837 | 0.010 |
Why?
|
| Exanthema | 1 | 2001 | 504 | 0.010 |
Why?
|
| Heart Failure | 1 | 2000 | 11832 | 0.010 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2000 | 566 | 0.010 |
Why?
|
| Insulin | 1 | 2010 | 6589 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 5039 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2003 | 1708 | 0.010 |
Why?
|
| Urban Population | 1 | 2003 | 2015 | 0.010 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 1995 | 69 | 0.010 |
Why?
|
| Pressure | 1 | 1998 | 1155 | 0.010 |
Why?
|
| Diarrhea | 1 | 2001 | 1340 | 0.010 |
Why?
|
| Streptokinase | 1 | 1994 | 187 | 0.010 |
Why?
|
| Consensus | 1 | 2003 | 3091 | 0.010 |
Why?
|
| Fibrinopeptide A | 1 | 1993 | 43 | 0.010 |
Why?
|
| Risk | 1 | 2005 | 9622 | 0.010 |
Why?
|
| Antithrombin III | 1 | 1993 | 129 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2003 | 2627 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2000 | 1877 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2003 | 8147 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2003 | 3916 | 0.010 |
Why?
|
| Autoimmunity | 1 | 2000 | 1358 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1997 | 1612 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2000 | 2238 | 0.010 |
Why?
|
| Mass Screening | 1 | 2003 | 5419 | 0.000 |
Why?
|
| Vascular Patency | 1 | 1990 | 904 | 0.000 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2000 | 4492 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 2006 | 26099 | 0.000 |
Why?
|
| Pain | 1 | 2001 | 5059 | 0.000 |
Why?
|
| Adenosine Triphosphate | 1 | 1990 | 1992 | 0.000 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1987 | 1343 | 0.000 |
Why?
|
| Kinetics | 1 | 1985 | 6373 | 0.000 |
Why?
|